Canary Islands Health Research Institute Foundation (FIISC), Tenerife, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Madrid, Spain.
JMIR Mhealth Uhealth. 2020 Nov 2;8(11):e18922. doi: 10.2196/18922.
Type 2 diabetes mellitus (T2DM) is a chronic disease in which health outcomes are related to decision making by patients and health care professionals.
This study aims to assess the effectiveness of internet-based multicomponent interventions to support decision making of all actors involved in the care of patients with T2DM in primary care.
The INDICA study is an open, community-based, multicenter trial with random allocation to usual care or the intervention for patients, the intervention for health care professionals in primary care, or the combined intervention for both. In the intervention for patients, participants received an educational group program and were monitored and supported by logs, a web-based platform, and automated SMS. Those in the intervention for professionals also received an educational program, a decision support tool embedded in the electronic clinical record, and periodic feedback about patients' results. A total of 2334 people with T2DM, regardless of glycated hemoglobin (HbA) levels and without diabetes-related complications, were included. The primary end point was change in HbA level. The main analysis was performed using multilevel mixed models.
For the overall sample, the intervention for patients attained a significant mean reduction in HbA levels of ‒0.27 (95% CI ‒0.45 to ‒0.10) at month 3 and ‒0.26 (95% CI ‒0.44 to ‒0.08) at month 6 compared with usual care, which remained marginally significant at month 12. A clinically relevant reduction in HbA level was observed in 35.6% (191/537) of patients in the intervention for patients and 26.0% (152/586) of those in usual care at month 12 (P=.006). In the combined intervention, HbA reduction was significant until month 18 (181/557, 32.6% vs 140/586, 23.9%; P=.009). Considering the subgroup of patients uncontrolled at baseline, all interventions produced significant reductions in HbA levels across the entire study period: ‒0.49 (95% CI ‒0.70 to ‒0.27) for the intervention for patients, ‒0.35 (95% CI ‒0.59 to ‒0.14) for the intervention for professionals, and ‒0.35 (95% CI ‒0.57 to ‒0.13) for the combined intervention. Differences in HbA for the area under the curve considering the entire period were significant for the intervention for patients and the combined intervention compared with usual care (P=.03 for both). Compared with usual care, the intervention for professionals and the combined intervention had significant longer-term reductions in systolic and diastolic blood pressure.
In uncontrolled patients, the intervention for patients at baseline provided clinically relevant and significant longer-term reductions of HbA levels. The intervention for professionals and combined intervention also improved the cardiovascular risk profile of patients.
ClinicalTrials.gov NCT01657227; https://clinicaltrials.gov/ct2/show/NCT01657227.
2 型糖尿病(T2DM)是一种慢性病,其健康结局与患者和医疗保健专业人员的决策有关。
本研究旨在评估基于互联网的多组分干预措施在支持 T2DM 患者护理中所有参与者决策方面的有效性,这些患者来自初级保健。
INDICA 研究是一项开放的、基于社区的、多中心试验,采用随机分配至常规护理或患者干预、初级保健中医疗保健专业人员的干预或两者的联合干预。在患者干预中,参与者接受了一个教育团体计划,并通过日志、基于网络的平台和自动短信进行监测和支持。那些接受专业人员干预的人还接受了一个教育计划、嵌入电子病历的决策支持工具以及关于患者结果的定期反馈。共纳入了 2334 名 T2DM 患者,无论糖化血红蛋白(HbA)水平如何,且没有糖尿病相关并发症。主要终点是 HbA 水平的变化。主要分析使用多级混合模型进行。
对于整个样本,与常规护理相比,患者干预在第 3 个月时 HbA 水平显著降低了-0.27(95%CI-0.45 至-0.10),在第 6 个月时降低了-0.26(95%CI-0.44 至-0.08),在第 12 个月时仍有边际显著差异。在第 12 个月时,患者干预中有 35.6%(191/537)的患者和常规护理中有 26.0%(152/586)的患者出现 HbA 水平的临床相关降低(P=.006)。在联合干预中,HbA 降低在第 18 个月时仍具有统计学意义(181/557,32.6% vs 140/586,23.9%;P=.009)。考虑到基线时未控制的患者亚组,所有干预措施在整个研究期间均显著降低了 HbA 水平:患者干预组降低了-0.49(95%CI-0.70 至-0.27),专业人员干预组降低了-0.35(95%CI-0.59 至-0.14),联合干预组降低了-0.35(95%CI-0.57 至-0.13)。考虑整个研究期间的曲线下面积,患者干预和联合干预与常规护理相比,HbA 的差异具有统计学意义(两者均为 P=.03)。与常规护理相比,专业人员干预和联合干预在收缩压和舒张压方面具有更长期的显著降低。
在未控制的患者中,基线时的患者干预提供了具有临床意义且显著的 HbA 水平的更长期降低。专业人员干预和联合干预也改善了患者的心血管风险状况。
ClinicalTrials.gov NCT01657227;https://clinicaltrials.gov/ct2/show/NCT01657227。